Ebola primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Ebola}}
{{Ebola}}
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{CMG}}
{{CMG}}
==Overview==
==Overview==

Revision as of 18:37, 14 December 2012

Ebola Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ebola from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Algorithm for the Evaluation of the Returned Traveler

Emergency Department Evaluation

Case Definition

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Hospital Preparedness

Checklists

Air Medical Transport

Monitoring and Movement Following Exposure

Primary Prevention

Future or Investigational Therapies

Postmortem Care

Postmortem Care

Case Studies

Case #1

Ebola primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ebola primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ebola primary prevention

CDC on Ebola primary prevention

Ebola primary prevention in the news

Blogs on Ebola primary prevention

Directions to Hospitals Treating ebola

Risk calculators and risk factors for Ebola primary prevention

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Vaccines have been produced for both Ebola [1] and Marburg[2] that were 99% effective in protecting a group of monkeys from the disease. These vaccines are based on either a recombinant Vesicular stomatitis virus or a recombinant Adenovirus[3] carrying the Ebola spikeprotein on its surface. Early human vaccine efforts, like the one at NIAID in 2003, have so far not reported any successes.[4] The biggest problem with the vaccine is that unless the patient is given it near the onset of the virus (1-4 days after the symptoms begin) then there will be too much damage to the human body to repair, ie: ruptured arteries and capillaries, vomiting, and other symptoms which may still cause enough harm to kill or seriously traumatize the patient.

References

  1. Jones, Steven (2005). "Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses". Nature Medicine. 11 (7): 786–790. doi:10.1038/nm1258. Unknown parameter |coauthors= ignored (help)
  2. Hevey, M (1998). "Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates". Virology. 251 (1): 28–37. doi:10.1006/viro.1998.9367. Unknown parameter |coauthors= ignored (help)
  3. Sullivan, Nancy (2003). "Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates". Nature. 424 (6949): 681–684. doi:10.1038/nature01876. Unknown parameter |coauthors= ignored (help)
  4. "NIAID Ebola Vaccine Enters Human Trial" (Press release). National Institute of Allergy and Infectious Diseases. 2003-11-18.

Template:WH Template:WS